With a deeper understanding of these mechanisms, the DARPP-32/CXCR4/CXCL-12 complex axis should be considered a type of targeted therapy to inhibit tumor progression and improve outcomes in patients with gastric cancer. This evidence concerns the gene CXCL12 and gastric cancer.